Emerging drugs for high-grade osteosarcoma

被引：104

作者：

Hattinger, Claudia Maria ^{[1
]}

Pasello, Michela ^{[1
]}

Ferrari, Stefano ^{[2
]}

Picci, Piero

Serra, Massimo ^{[1
]}

机构：

[1] Rizzoli Orthopaed Inst, Pharmacogenom & Pharmacogenet Res Unit, Expt Oncol Lab, I-40136 Bologna, Italy

[2] Rizzoli Orthopaed Inst, Dept Chemotherapy, I-40136 Bologna, Italy

来源：

EXPERT OPINION ON EMERGING DRUGS | 2010年 / 15卷 / 04期

关键词：

drug resistance; osteosarcoma; tailored therapy; target-specific drugs; therapeutic markers; PHASE-I TRIAL; ZOLEDRONIC ACID; P-GLYCOPROTEIN; METHOTREXATE RESISTANCE; MURAMYL TRIPEPTIDE; PREOPERATIVE CHEMOTHERAPY; DIHYDROFOLATE-REDUCTASE; OSTEOGENIC-SARCOMA; PROGNOSTIC-FACTORS; ABC TRANSPORTERS;

D O I：

10.1517/14728214.2010.505603

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Importance of the field: Osteosarcoma (OS) is the most common primary malignant bone tumour in children and adolescents. This review focuses on the most promising therapeutic markers and drugs which may potentially be considered for innovative high-grade OS treatments. Areas covered in this review: The list of drugs and compounds reviewed has been generated by taking into account those which target markers of potential clinical interest for high-grade OS and have been included in Phase I, II or III clinical trials. The literature search covers the last 40 years, starting from the first OS chemotherapy reports of the early 1970s. Particular relevance was given to reports and reviews on new targeted therapies of possible clinical usefulness for high-grade OS. What the reader will gain: This review gives an updated overview of novel therapeutic approaches which have been or are going to be evaluated in Phase I/II/III clinical studies for high-grade OS. Take home message: On the basis of the information that has emerged so far, it can be predicted that in the next 5 - 10 years, new agents to be included in innovative treatment strategies for selected subgroups of high-grade OS patients may become available.

引用

页码：615 / 634

页数：20

共 104 条

[1] Correlation Between Clinical Outcome and Growth Factor Pathway Expression in Osteogenic Sarcoma [J].

Abdeen, Ayesha ;

Chou, Alexander J. ;

Healey, John H. ;

Khanna, Chand ;

Osborne, Tanasa S. ;

Hewitt, Stephen M. ;

Kim, Mimi ;

Wang, Dan ;

Moody, Karen ;

Gorlick, Richard .

CANCER, 2009, 115 (22) :5243-5250

[2] Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway [J].

Akiyama, Toru ;

Dass, Crispin R. ;

Choong, Peter F. M. .

MOLECULAR CANCER THERAPEUTICS, 2008, 7 (11) :3461-3469

[3]

Anderson P, 2008, EXPERT OPIN INV DRUG, V17, P1703, DOI [10.1517/13543784.17.11.1703, 10.1517/13543784.17.11.1703 ]

[4] Inhibitory effect of curcumin on MDR1 gene expression in patient leukemic cells [J].

Anuchapreeda, Songyot ;

Thanarattanakorn, Paftra ;

Sittipreechacharn, Sornjai ;

Tima, Singkome ;

Chanarat, Prasit ;

Limtrakul, Pornngarm .

ARCHIVES OF PHARMACAL RESEARCH, 2006, 29 (10) :866-873

[5] Insulin Receptor Isoform A and Insulin-like Growth Factor II as Additional Treatment Targets in Human Osteosarcoma [J].

Avnet, Sofia ;

Sciacca, Laura ;

Salerno, Manuela ;

Gancitano, Giovanni ;

Cassarino, Maria Francesca ;

Longhi, Alessandra ;

Zakikhani, Mahvash ;

Carboni, Joan M. ;

Gottardis, Marco ;

Giuti, Armando ;

Pollak, Michael ;

Vigneri, Riccardo ;

Baldini, Nicola .

CANCER RESEARCH, 2009, 69 (06) :2443-2452

[6] Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy - 15-year experience in 789 patients treated at a single institution [J].

Bacci, G ;

Longhi, A ;

Versari, M ;

Mercuri, M ;

Briccoli, A ;

Picci, P .

CANCER, 2006, 106 (05) :1154-1161

[7] Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli according to the Istituto Ortopedico Rizzoli Osteosarcoma-2 protocol: An updated report [J].

Bacci, G ;

Ferrari, S ;

Bertoni, F ;

Ruggieri, P ;

Picci, P ;

Longhi, A ;

Casadei, R ;

Fabbri, N ;

Forni, C ;

Versari, M ;

Campanacci, M .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (24) :4016-4027

[8] EXPRESSION OF P-GLYCOPROTEIN IN HIGH-GRADE OSTEOSARCOMAS IN RELATION TO CLINICAL OUTCOME [J].

BALDINI, N ;

SCOTLANDI, K ;

BARBANTIBRODANO, G ;

MANARA, MC ;

MAURICI, D ;

BACCI, G ;

BERTONI, F ;

PICCI, P ;

SOTTILI, S ;

CAMPANACCI, M ;

SERRA, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (21) :1380-1385

[9] Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells [J].

Benassi, Maria Serena ;

Chiechi, Antonella ;

Ponticelli, Francesca ;

Pazzaglia, Laura ;

Gamberi, Gabriella ;

Zanella, Licciana ;

Manara, Maria Cristina ;

Perego, Paola ;

Ferrari, Stefano ;

Picci, Piero .

CANCER LETTERS, 2007, 250 (02) :194-205

[10]

Benini S, 1999, INT J CANCER, V80, P581, DOI 10.1002/(SICI)1097-0215(19990209)80:4<581::AID-IJC16>3.0.CO

← 1 2 3 4 5 6 7 8 9 10 →